Teriparatide (PTH 1-34) Process
Osteoporosis
CommercialActive
Key Facts
About Numaferm
Numaferm is a Hamburg-based biotech firm operating at the intersection of synthetic biology and biologics production. The company has developed two core technology platforms: Numascreen™ for high-diversity phage display-based lead discovery and Numatech™ for high-titer, cost-effective microbial expression. With an ISO 9001:2015 certified operation and a team of ~30 experts, Numaferm serves as a service provider and partner for pharmaceutical, agricultural, and industrial clients, aiming to democratize access to peptide and protein-based solutions. Its business model combines fee-for-service projects with technology licensing and process development partnerships.
View full company profileTherapeutic Areas
Other Osteoporosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar to Prolia® (denosumab) | Teva | Approved/Under Review |
| Teriparatide | Epygen Biotech | Not Disclosed |
| AGA2118 | Angitia Biopharmaceuticals | Phase 2 |
| Recombinant Teriparatide | Paras Biopharmaceuticals Finland | Pre-clinical |
| Stoboclo®/Osenvelt® | Celltrion | Marketed |
| SHR-1222 | Jiangsu Hengrui Medicine | Phase III |
| Biosimilar Denosumab | Richter Gedeon | Phase III |
| Teriparatide Injection | Amphastar Pharmaceuticals | Marketed |
| TST002 (Blosozumab) | Transcenta Therapeutics | Phase 1 |